Revance Therapeutics - News & Publications

News & Publications

	Revance Announces Series D Financing (01/04/10)
	Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin (07/28/09)
	Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles (07/10/09)
	Revance Secures $8 Million in New Financing (11/18/08)

	Topical Botulinum Toxin Type A for the Treatment of Moderate to Severe Lateral Canthal Lines: Preliminary Safety and Efficacy Results of a Blinded, Randomized, Placebo Controlled Trial
	Safety and Tolerability of Topical Botulinum Toxin Type A in Healthy Adults
	A Phase 1, Randomized, Placebo-Controlled, Safety and Efficacy Study of a Botulinum Toxin Type A Topical Gel for Treatment of Lateral Canthal Lines
	Preclinical Transcutaneous Flux Experiments Using a Macromolecule Transport System (MTS) Peptide for Delivery of Botulinum Toxin Type A
	Cosmetic Dermatology, March 2007 - "Improving Elasticity: The Science of Aging Skin"
	Topically Applied Botulinum Toxin Type A for the Treatment of Primary Axillary Hyperhidrosis: Results of a Randomized, Blinded, Vehicle-Controlled Study